AML-547 Prognostic Effect of Co-Mutations on Patients With NPM1+ Acute Myeloid Leukemia (AML) Enrolled in the Connect® Myeloid Registry

• Published in: Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2023-09, Vol.23, p.S311-S312
• Main Authors: Maciejewski, Jaroslaw, Pollyea, Daniel, Roboz, Gail, Seiter, Karen, Scott, Bart, DeGutis, Irene, Kiselev, Pavel, Yu, Edward, McBride, Ali, Heydendael, Willem, Erba, Harry
• Format: Article
• Language: English
• Subjects: acute myeloid leukemia; AML; biomarkers; NPM1; RUNX1; TP53
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/S2152-2650(23)01079-0

The 2017 World Health Organization classification of myeloid neoplasms and acute myeloid leukemia (AML) recognizes AML with mutated NPM1 as a distinct entity with favorable prognosis. However, mutations other than NPM1 may further influence disease prognosis. To assess the prognostic effect of NPM1 co-mutations in patients with AML enrolled in the Connect® Myeloid Registry (NCT01688011). The registry is a large, U.S., multicenter, prospective observational cohort study of patients with newly diagnosed AML, myelodysplastic syndromes, idiopathic cytopenia of undetermined significance, or myelofibrosis. In this analysis, patients with AML ≥55 years of age were grouped by known NPM1 status (NPM1+ vs NPM1–). The frequency of gene mutations was analyzed among patients with NPM1+ AML and NPM1– AML. OS was evaluated using the Cox model adjusted for age and mutations in TP53 and RUNX1. Overall, 123 patients with NPM1+ AML and 360 patients with NPM1– AML were included. Most patients were male (NPM1+, 61.5%; NPM1−, 60.7%) and white (NPM1+, 78.0%; NPM1−, 85.6%); median (range) age was 67 (55-87) and 71 (55-97) years for the NPM1+ and NPM1− groups, respectively. After adjusting for age, patients with NPM1+ AML had significantly longer median OS than patients with NPM1– AML (26 vs 15 months; HR [95% CI]: 0.58 [0.44-0.76]; P